Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study

Ellen Grober, Richard B Lipton, Reisa A Sperling, Kathryn V Papp, Keith A Johnson, Dorene M Rentz, Amy E Veroff, Paul S Aisen, Ali Ezzati, Ellen Grober, Richard B Lipton, Reisa A Sperling, Kathryn V Papp, Keith A Johnson, Dorene M Rentz, Amy E Veroff, Paul S Aisen, Ali Ezzati

Abstract

Background and objectives: The goal of this work was to investigate the neuroimaging correlates of the Stages of Objective Memory Impairment (SOMI) system operationalized with the Free and Cued Selective Reminding Test (FCSRT), a widely used episodic memory measure.

Methods: The FCSRT begins with a study phase in which items (e.g., grapes) are identified in response to unique semantic cues (e.g., fruit) that are used in the test phase to prompt recall of items not retrieved by free recall. There are 3 test trials of the 16 items (maximum 48). Data from 4,484 cognitively unimpaired participants from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study were used. All participants had amyloid PET imaging, and a subset of 1,262 β-amyloid (Aβ)-positive had structural MRIs. We compared the Aβ mean cortical standardized uptake value ratio (SUVR) and volumetric measures of hippocampus, parahippocampal gyrus, entorhinal cortex, and inferior temporal cortex between the 5 SOMI stages.

Results: Participants had a mean age of 71.3 (SD 4.6) years; 40.6% were male; and 34.6% were APOE ε4 positive. Half had no memory impairment; the other half had retrieval deficits, storage limitations, or both. Analysis of covariance in the entire sample while controlling for age, sex, education, and APOE ε4 showed that individuals in higher SOMI stages had higher global amyloid SUVR (p < 0.001). Both SOMI-4 and -3 subgroups had higher amyloid SUVR than SOMI-0 and SOMI-1 subgroups. Individuals in higher SOMI stages had smaller hippocampal volume (p = 0.003), entorhinal cortex (p < 0.05), and inferior temporal lobes (p < 0.05), but there was no difference between parahippocampal gyrus volume of different SOMI stages. Pairwise comparison of SOMI subgroups showed that the SOMI-4, -3, and -2 subgroups had smaller hippocampal volume than the SOMI-0 and -1 subgroup. The SOMI-4 subgroup had significantly smaller entorhinal cortex and smaller inferior temporal lobe compared to all other groups.

Discussion: Presence of Alzheimer disease pathology is closely related to memory impairment according to SOMI stages in the cognitively unimpaired sample of A4. Results from structural MRIs suggest that memory storage impairment (SOMI-3 and -4) is present when there is widespread medial temporal lobe atrophy.

Trial registration information: ClinicalTrials.gov identifier: NCT02008357.

Classification of evidence: This study provides Class I evidence that, in normal older individuals, higher stages of memory impairment assessed with FCSRT were associated with higher amyloid imaging burden and lower volume of hippocampus, entorhinal cortex, and inferior temporal lobes.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Boxplot Comparing Amyloid PET SUVR…
Figure 1. Boxplot Comparing Amyloid PET SUVR Across Different SOMI Subgroups for the Whole Population (A) and Sample Stratified According to Aβ Status (B)
Groups significantly different from each other are connected to each other with brackets (p < 0.005). Aβ = β-amyloid; SOMI = Stages of Objective Memory Impairment; SUVR = standardized uptake value ratio.
Figure 2. Volume of Different Regions by…
Figure 2. Volume of Different Regions by SOMI Stage
Volumetric measures are normalized and rescaled to 0 to 1 to improve comparability. Groups significantly different from each other (p < 0.005) are connected to each other with lines. SOMI = Stages of Objective Memory Impairment.

References

    1. Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
    1. Dubois B, Epelbaum S, Nyasse F, et al. . Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17(4):335-346.
    1. Sarazin M, Chauvire V, Gerardin E, et al. . The amnestic syndrome of hippocampal type in Alzheimer's Disease: an MRI study. J Alzheimer's Dis. 2010;22:285-294.
    1. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915-924.
    1. Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults. Ann Clin Transl Neurol. 2020;7(5):776-785.
    1. Xie J, Gabelle A, Dorey A, et al. . Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature. J Alzheimers Dis. 2014;41(4):1109-1116.
    1. Wagner M, Wolf S, Reischies FM, et al. . Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78(6):379-386.
    1. Slachevsky A, Barraza P, Hornberger M, et al. . Neuroanatomical comparison of the "word" and “picture” versions of the Free and Cued Selective Reminding Test in Alzheimer's disease. J Alzheimers Dis. 2018;61(2):589-600.
    1. Bernard CC. PCC characteristics at rest in 10-year memory decliners. Neurobiol Aging. 2015;36(10):2812-2820.
    1. Zammit AR, Ezzati A, Zimmerman ME, Lipton RB, Lipton ML, Katz MJ. Roles of hippocampal subfields in verbal and visual episodic memory. Behav Brain Res. 2017;317:157-162.
    1. Ezzati A, Katz MJ, Zammit AR, et al. . Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults. Neuropsychologia. 2016;93(Pt B):380-385.
    1. Derby CA, Burns LC, Wang C, et al. . Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology. 2013;80(14):1307-1314.
    1. Katz MJ, Lipton RB, Hall CB, et al. . Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in Blacks and Whites: a report from the Einstein Aging Study. Alzheimer Dis Associated Disord. 2012;26(4):335-343.
    1. Sarazin M, Berr C, De Rotrou J, et al. . Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69(19):1859-1867.
    1. Di Stefano F, Epelbaum S, Coley N, et al. . Prediction of Alzheimer's disease dementia: data from the GuidAge prevention trial. J Alzheimers Dis. 2015;48(3):793-804.
    1. Lemos R, Maroco J, Simoes MR, Santiago B, Tomas J, Santana I. The Free and Cued Selective Reminding Test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a prospective longitudinal study. J Neuropsychol. 2017;11(1):40-55.
    1. Teichmann M, Epelbaum S, Samri D, et al. . Free and Cued Selective Reminding Test: accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: a large-scale biomarker-characterized monocenter cohort study (ClinAD). Alzheimers Dement. 2017;13(8):913-923.
    1. Auriacombe S, Helmer C, Amieva H, Berr C, Dubois B, Dartigues JF. Validity of the Free and Cued Selective Reminding Test in predicting dementia: the 3C study. Neurology. 2010;74(22):1760-1767.
    1. Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3(1):13-36.
    1. Tulving E. Elements of Episodic Memory. Oxford University Press; 1983.
    1. Grober E, An Y, Lipton RB, Kawas C, Resnick SM. Timing of onset and rate of decline in learning and retention in the pre-dementia phase of Alzheimer's disease. J Int Neuropsychol Soc. 2019;25(7):699-705.
    1. Papp KV, Rentz DM, Mormino EC, et al. . Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017;88(15):1431-1438.
    1. Grober E, Veroff AE, Lipton RB. Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the predementia phase of Alzheimer's disease: implications for clinical trials. Alzheimers Dement. 2018;10:161-171.
    1. Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
    1. Sperling RA, Donohue MC, Raman R, et al. . Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735-745.
    1. Pontecorvo MJ, Arora AK, Devine M, et al. . Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44(5):825-837.
    1. Johnson KA, Sperling RA, Gidicsin CM, et al. . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5):S72-S83.
    1. Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774-781.
    1. Karas G, Sluimer J, Goekoop R, et al. . Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol. 2008;29(5):944-949.
    1. Tanpitukpongse TP, Mazurowski MA, Ikhena J, Petrella JR. Predictive utility of marketed volumetric software tools in subjects at risk for Alzheimer disease: do regions outside the hippocampus matter?. AJNR Am J Neuroradiol. 2017;38(3):546-552.
    1. Grober E, Papp K, Rentz D, et al. . Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system. Alzheimers Dement. 2021;13(1):e12224.
    1. Mormino EC, Papp KV, Rentz DM, et al. . Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. 2017;13(9):1004-1012.
    1. Hyman BT, Phelps CH, Beach TG, et al. . National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer Dement. 2012;8(1):1-13.
    1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
    1. Chang Y-L, Bondi MW, Fennema-Notestine C, et al. . Brain substrates of learning and retention in mild cognitive impairment diagnosis and progression to Alzheimer's disease. Neuropsychologia. 2010;48(5):1237-1247.
    1. Duke Han S, Nguyen CP, Stricker NH, Nation DA. Detectable neuropsychological differences in early preclinical Alzheimer's disease: a meta-analysis. Neuropsychol Rev. 2017;27(4):305-325.
    1. Thomas KR, Edmonds EC, Eppig J, Salmon DP, Bondi MW. Using neuropsychological process scores to identify subtle cognitive decline and predict progression to mild cognitive impairment. J Alzheimers Dis. 2018;64(1):195-204.
    1. Thomas KR, Bangen KJ, Weigand AJ, et al. . Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology. 2020;94(4):e397-e406.

Source: PubMed

3
Abonneren